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Background: Studies investigating the association between hepatitis C virus (HCV) infections and the occurrence
of cholangiocarcinoma (CCA), especially intrahepatic cholangiocarcinoma (ICC), have shown inconsistent findings.
Although previous meta-analyses referred to HCV and CCA, they mainly focused on ICC rather than CCA or extrahepatic
cholangiocarcinoma (ECC). Since then, relevant new studies have been published on the association between HCV and
ICC. Since the different anatomic locations of CCA have distinct epidemiologic features and different risk factors, it is
necessary to evaluate the relationship between HCV infection and ICC, ECC, and CCA.
Methods: Relevant studies were identified by searching PUBMED, EMBASE, and MEDLINE databases prior to 1 August
2013. Pooled risk estimates were calculated with random-effects models using STATA 11.0.
Results: A total of 16 case-control studies were included in the final analysis. Pooled risk estimates showed a statistically
significant increasing risk of CCA (odds ratio (OR) = 5.44, 95% CI, 2.72 to 10.89). The pooled risk estimate of ICC (OR = 3.38,
95% CI, 2.72 to 4.21) was higher than that of ECC (OR = 1.75, 95% CI, 1.00 to 3.05). In a subgroup analysis, the pooled risk
estimate of ICC in studies from North America was obviously higher than in Asia (6.48 versus 2.01). The Begg funnel plot
and Egger test showed no evidence of publication bias.
Conclusions: HCV infection is associated with the increasing risk of CCA, especially ICC.
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Cholangiocarcinoma (CCA) is a malignant neoplasm
arising from the epithelial cells of the intrahepatic or ex-
trahepatic bile ducts. Therefore, CCA can be classified
as intrahepatic cholangiocarcinoma (ICC) and extrahe-
patic cholangiocarcinoma (ECC). CCA is the second
most common primary hepatic malignancy, representing
10% to 25% of primary hepatic malignancies worldwide,
accounting for 3% of all gastrointestinal tumors [1-3]. It* Correspondence: zhengyunzh@yahoo.com.cn; gwzhousfph@163.com
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rate, with a median survival of less than 24 months [4].
Defining the risk factors for CCA benefits the search
for better ways to prevent the occurrence of this disease.
To date, it has been shown that hepatolithiasis, primary
sclerosing cholangitis, liver flukes, biliary duct cysts, specific
toxins (for example, the carcinogenic agent thorotrast), in-
flammatory bowel disease, and genetic polymorphisms are
the major risk factors for CCA [5-8]. Although the associ-
ation between CCA and viral hepatitis infections has been
examined in several studies, the results remain controver-
sial, especially for the hepatitis C virus (HCV) [7,9-15].
Several case-control studies have suggested that HCV infec-
tion plays a major role in CCA development [9-14]. Inis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tions between CCA and HCV [7,15]. Therefore, in the
present study, we performed a systematic review and meta-




Two independent reviewers searched PUBMED, EMBASE,
and MEDLINE databases prior to 1 August 2013. The
MeSH (Medical Subject Heading) search included headings
that were all combinations of the hepatitis C virus such as:
HCV, cholangiocarcinoma, intrahepatic, extrahepatic, bile
duct cancer, and bile duct neoplasm. We also reviewed the
reference lists of retrieved articles to search for more rele-
vant studies. There were no language restrictions.
Inclusion and exclusion criteria
Studies were eligible if they met the following criteria:
(1) case-control studies; (2) exposure to HCV infection;
(3) the outcome was CCA, ICC, or ECC incidence; and
(4) providing risk estimates with 95% confidence interval
(CI) or available information to calculate them. Abstracts,
letters, reviews, case reports, studies lacking control groups,
and studies that did not provide sufficient data to calculate
risk estimates were excluded. Two investigators independ-
ently selected studies, and any discrepancies were resolved
by consensus.
Data extraction
For each eligible study, the following parameters were
extracted independently by two researchers: (1) first au-
thor’s last name, date of study publication and the coun-
try where the study was conducted; (2) study design; (3)
type of control; (4) sample size and age; (5) number of
exposure in cases and controls; (6) risk estimate and
95% CI; and (7) adjustments and other information. The
present meta-analysis included different measures of risk
estimates (odds ratio, incidence rate ratio, standardized
incidence ratio, and hazard ratio). In fact, the different
measures yielded a similar risk estimate due to the rela-
tively scarce occurrence of cholangiocarcinoma.
Statistical analysis
A pooled risk estimate was calculated with a random-
effects model, considering both intra-study and inter-
study variances. Statistical heterogeneity was evaluated
using the Q and I2 statistics. For the Q statistic, P < 0.10
was used as an indication of the existence of hetero-
geneity. Subgroup analysis was performed to explore
potential heterogeneity among studies. Publication
bias was assessed using the Begg funnel plot and the
Egger test, and a P < 0.10 was considered as an indica-
tor for publication bias [16,17]. All statistical analyseswere conducted using STATA 11.0 for Windows (Stata,
College Station, TX, USA).
Results
Search results
A total of 159 articles were identified through the litera-
ture search. Of these, 146 studies were excluded because
they were either review articles, case reports, letters, or
were not case-control studies. Studies were excluded
when exposure was not an HCV infection and outcomes
were not CCA, ICC, or ECC. The remaining 13 case-
control studies, plus 8 studies from the reference lists,
added 21 studies, of which 5 were excluded because of
duplicates from the same population and risk estimates
were not available. After strict screening, a total of 16
case-control studies were ultimately included in the
present study [7,9-15,17-24] (Figure 1). The main fea-
tures of these studies are shown in Table 1. We identi-
fied 16 case-control studies from 1991 to 2012. Four
studies were from the USA [12-14,23], six from China
[7,15,18,20,22,24], one from Taiwan [19], two from
South Korea [9,17], one from Italy [10], one from Japan
[11], and one from Thailand [21]. Data of a total of
3,658 patients with ICC and 1,280 with ECC were re-
ported in these case-control studies. One study including
103 CCA cases did not classify ICC and ECC [21].
Among 5,044 cases, data of 140 patients with HCV in-
fection were reported, whereas among 396,887 control
subjects, data of a total of 1,879 subjects with HCV in-
fection were reported. The diagnosis of CCA was con-
firmed by pathological examination. HCV infection was
confirmed by laboratory tests. Controls recruited origi-
nated from hospital-based [7,9-11,13,15,17,19-22,24] or
general population-based groups [12,14,18,23]. Control
subjects [9-11,15,19,21] were selected from patients with
non-liver-related cancer or other non-cancer disease and
from healthy individuals at health screening centers of
hospitals in four studies [13,17,20,22]. Qu et al. [24] se-
lected participants with benign biliary disease with
cholelithiasis or acute cholangitis as controls, whereas
Liu et al. [7] selected patients with hepatolithiasis alone as
controls. In 15 of the selected 16 studies, age-matched and
sex-matched controls were used [7,9-15,17,19-24]. One
study had two control groups [9]. Eight studies found a sta-
tistically significant positive association between HCV and
ICC (odds ratio (OR) = 2.5 to 9.7) [9-14,19,23]. Four studies
did not find a positive association between HCV and ICC
[7,15,17,18], whereas two studies did not report the risk es-
timates [22,24].
HCV infection and the risk of CCA
We identified four case-control studies [13,14,20,21]
reporting the association between HCV infection and
the risk of CCA. All four studies found a positive
Figure 1 Flow chart of the selection and disposition of studies. A total of 159 relevant studies were identified during the initial search, and 16
studies remained after careful screening.












Liu (2011) [7] China ICC ≧50 39 87 228 Hospital-based 0.87 (0.09 to 18.50) NR
Shin (1996) [9] Korea ICC 59 73.2 41 406 Hospital-based 6.80 (2.30 to 20.30) age, sex
Donato (20011) [10] Italy ICC 65 80.8 26 824 Hospital-based 9.70 (1.60 to 58.90) sex, age, residence
Zhou (2008) [15] China ICC 53.2 66 312 438 Hospital-based 0.93 (0.28 to 3.10) age, sex
Shaib (2005) [12] United States ICC 78.7 51.7 625 90,834 Population-based 6.10 (4.30 to 8.60) age, sex, race, geographic
location,
Shaib (2007) [13] United States ICC 59.8 55.4 83 236 Hospital-based 7.90 (1.30 to 84.50) age, ethnicity, anti-HCV,
HbsAg anti-HBc,
alcohol consumptionECC 61.1 67.6 163 2.80 (0.30 to 35.10)
Yamamoto
(2004) [11]
Japan ICC 64.6 58 50 205 Hospital-based 6.02 (1.51 to 24.1) aspartate aminotransferase,
blood transfusion,
diabetes mellitus
Welzel (2007) [14] United States ICC 79 48 535 102,782 Population-based 4.40 (1.40 to 140) age, race, geographic region
ECC 78.7 51 549 1.50 (0.20 to 11.00)
Lee (2008) [17] South Korea ICC 60.7 69.1 622 2,488 Hospital-based 1.00 (0.50 to 1.90) age, sex
Hsing (2008) [18] China ECC 67 58.2 134 762 Population-based 0.80 (0.20 to 3.40) education, smoking, BMI,
diabetes, gallstones
Tao (2009) [20] China ICC ≧50 60.7 61 380 Hospital-based 6.30 (0.40 to 102.30) NR
Lee (2009) [19] Taiwan, Republic
of China
ICC 61.5 63.1 160 160 Hospital-based 2.71 (1.16 to 6.32) NR
Srivatanakul
(2010) [21]
Thailand CCA NR NR 103 103 Hospital-based 7/0 (1.44 to infinity) anti-OV Ab
Welzel (2011) [23] United States ICC 76.4 47.5 743 195,953 Population-based 8.05 (5.08 to 12.75) age, sex, race,
geographic location
Cai (2011) [22] China ICC 56.6 62.0 313 608 Hospital-based NR NR
Qu (2012) [24] China ECC 63 63.9 305 480 Hospital-based NR NR
M, male; Y, year; CCA, cholangiocarcinoma; ECC, extrahepatic cholangiocarcinoma; ICC, intrahepatic cholangiocarcinoma; CI, confidence interval; OR, odds ratio;
NR, not reported; BMI, body mass index; OV, opisthorchis viverrini; Ab, antibody.
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2.49 to 13.99). In the present study, the meta-analysis of
four case-control studies showed an OR of 5.44 (95% CI,
2.72 to 10.89) (Figure 2). The heterogeneity was not
significant (I2 = 0.0%, P = 0.704).
HCV infection and the risk of ICC
We found a statistically significant positive association
between HCV infection and ICC incidence (OR = 3.38,
95% CI, 2.72 to 4.21, P < 0.001) in a random-effects
model in the meta-analysis for 13 case-control studies
[7,9-15,17,19,20,22,23], (Figure 3). In this meta-analysis,
we found significant heterogeneity among the case-
control studies (Q = 64.32, I2 = 81.3%, P < 0.001). In order
to explore potential sources of heterogeneity, we con-
ducted subgroup analyses by geographic region, sources,
control groups, and adjusted covariates (Table 2).
Among 13 case-control studies, 8 studies were from
Asia [7,9,11,15,17,19,20,22], 4 from North America
[12-14,23], and 1 from Europe [10]. The pooled OR of
North American studies (OR = 6.48, 95% CI, 4.97 to 8.46)
was higher than that of Asian studies (OR = 2.01, 95% CI,
1.44 to 2.79) and the European study (OR = 4.64, 95% CI,
1.79 to 12.08). The heterogeneity was significant in Asian
studies (I2 = 77.30%, P < 0.001), but not in North American
studies. The pooled ORs were 2.24 (95% CI, 1.65 to 3.05)
for studies with hospitalized controls and 3.38 (95% CI,
2.72 to 4.21) with population-based controls. The hetero-
geneity was significant only in studies with hospitalized
controls (I2 = 74.20%, P < 0.001).
HCV infection and the risk of ECC
Five case-control studies reported results on HCV
and ECC [13,14,18,20,24]. Among these studies, threeFigure 2 Forest plot of cholangiocarcinoma risk associated with HCV infection.
CCA incidence was found (OR = 5.44, 95% CI, 2.72 to 10.89) in a random-effectsstudies [13,14,20] showed a statistically significant posi-
tive association between HCV and ECC (OR = 4.47 to
9.02), and two studies [18,24] showed no significant
positive associations (OR = 0.75 to 0.78). In our meta-
analysis of these studies, the pooled risk estimate was
1.75 (95% CI, 1.00 to 3.05) in a random-effects model
(Figure 4).
In the subgroup analysis (Table 2), three studies were
from Asia, and two from North America. The pooled
OR of North American studies (OR = 4.88, 95% CI, 1.88
to 12.65) was higher than that of Asian studies (OR =
1.06, 95% CI, 0.52 to 2.19). No significant heterogeneity
was shown in any of the subgroups. The pooled ORs
were 1.66 (95% CI, 0.81 to 3.41) for studies with hospi-
talized controls and 1.91 (95% CI, 0.81 to 4.50) with
population-based controls. Significant heterogeneity was
found between studies with hospitalized controls and
studies with population-based controls.
Publication bias
Funnel plots showed no publication bias in studies
concerning CCA, ICC, and ECC (Figure 5). P values
for Begg’s adjusted rank correlation test and Egger’s
regression asymmetry test were positive (P > 0.05),
suggesting that publication bias had little effect on
summary estimates.
Discussion
The global prevalence of CCA has shown a rising trend
in recent years, and the incidence of HCV infection is
also found to be elevated [2,25-28]. Although many re-
searchers have focused on the association between HCV
infection and the risk of CCA, the findings have varied
due to differences between the studies in geographicA statistically significant positive association between HCV infection and
model in the meta-analysis of four case-control studies.
Figure 3 Forest plot of intrahepatic cholangiocarcinoma risk associated with HCV infection. A statistically significant positive association between
HCV infection and ICC incidence was found (OR = 3.38, 95% CI, 2.72 to 4.21, P < 0.001) in a random-effects model in the meta-analysis of 13
case-control studies.
Li et al. World Journal of Surgical Oncology  (2015) 13:161 Page 5 of 8regions, study design, sample size, and controls. Also, in
previous meta-analyses, adjusted risk estimates were
used rather than the unadjusted risk estimates used in
the present study. Regarding the potential confounding
factors for CCA, summary risk estimates are more pre-






Hospital-based 10 2.24 (1.65 to
Population-based 3 3.38 (2.72 to
Geographic region
North America 4 6.48 (4.97 to
Asia 8 2.01 (1.44 to
Europe 1 4.64 (1.79 to
ECC 5
Control group
Hospital-based 3 1.66 (0.81 to
Population-based 2 1.91 (0.81 to
Geographic region
North America 2 4.88 (1.88 to
Asia 3 1.06 (0.52 to
OR, odds ratio; CI, confidence interval; ECC, extrahepatic cholangiocarcinoma; ICC, inmodels. Although previous studies referred to HCV and
CCA, they mainly focused on HBV rather than HCV,
and ICC rather than ECC or CCA [29,30]. Further, just
as different anatomic locations of CCA have distinct epi-
demiologic features and different risk factors [13], ICC
and ECC also have many differences. The present studyontrol studies
Tests for heterogeneity
Q P value I2 (%)
3.05) 34.93 <0.001 74.20
4.21) 2.43 0.297 17.60
8.46) 2.44 0.486 0
2.79) 30.83 <0.001 77.30
12.08) 0 0
3.41) 5.80 0.055 65.50
4.50) 5.54 0.019 81.90
12.65) 0.04 0.845 0
2.19) 3.98 0.137 49.7%
trahepatic cholangiocarcinoma.
Figure 4 Forest plot of extrahepatic cholangiocarcinoma risk associated with HCV infection. The pooled risk estimate was 1.75
(95% CI, 1.00 to 3.051).
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HCV and CCA, including ICC and ECC. Moreover, the
16 case-control studies included in our meta-analysis ex-
ceed the number of studies included in previous meta-
analysis. Therefore, results and conclusions of our data
analysis are more reliable than previously published
meta-analyses. The present meta-analysis was conducted
to evaluate the relationship between HCV infection and
the risk of ICC, ECC, and CCA and was not confined to
associations between HCV and ICC.
The present study found that patients with an HCV
infection have an approximately 5.44-fold increased risk
of CCA compared to individuals with a non-HCV infec-
tion. In the study by Srivatanakul et al. [21], the OR for
CCA was 4.00. These results indicate that HCV is asso-
ciated with CCA incidence. To gain insight into the as-
sociation between HCV and CCA, we classified CCAFigure 5 Funnel plot of four studies. (a) No publication bias was found betwe
(P= 0.308) and Egger’s regression asymmetry test (P= 0.485). Funnel plot of 13
risk using Begg’s adjusted rank correlation test (P= 0.951) and Egger’s regression
was found between HCV infection and ECC risk using Begg’s adjusted rank corrinto ICC and ECC. The pooled OR of ICC (OR = 3.38,
95% CI, 2.72 to 4.21) was higher than that of ECC
(OR = 1.75, 95% CI, 1.00 to 3.05). This can probably be
explained by the different anatomic locations of CCA,
which were associated with different risk factors for
CCA. From these results, we concluded that ICC was
probably more susceptible to HCV infection than ECC.
In subgroup analysis of HCV and the risk of ICC in dif-
ferent geographic regions, the pooled OR was obviously
higher in studies from North America than those from
Asia (6.48 versus 2.01). This phenomenon was also seen
in the subgroup analysis of HCV and the risk of ECC
(4.88 versus 1.06) in the different geographic regions.
This might be explained by the fact that hepatitis C was
the most prevalent form of viral hepatitis infection in
Western countries compared to Asian countries. As
many studies have reported, ICC incidence is rising inen HCV infection and CCA risk using Begg’s adjusted rank correlation test
studies; (b) no publication bias was found between HCV infection and ICC
asymmetry test (P= 0.606). Funnel plot of 5 studies; (c) no publication bias
elation test (P= 0.221) and Egger’s regression asymmetry test (P= 0.495).
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ferences have led to different risk factors and epidemio-
logical factors associated with ICC [2,29,31,32]. In
subgroup analyses of controls, studies using hospital-
based controls and those using population-based con-
trols had similar risk estimates for ICC (2.24 versus 3.38)
and ECC (1.66 versus 1.91).
The mechanism of CCA development in patients with
HCV infection has not yet been clarified in detail. One
study suggests that the presence of HCV in the bile duct
epithelium indicates that HCV infection can cause
chronic inflammation of the bile duct epithelium [33].
Long-term expression of HCV oncoproteins may be
involved in the tumourigenic process leading to tumor
formation [34]. Another study reported that HCV core
variants could alleviate TGF-beta cytostatic responses and
increase TGF-beta-mediated epithelial-to-mesenchymal
transition (EMT), thereby promoting cell invasion and
metastasis [35]. Likewise, Chen et al. [36] found that HCV
core protein promoted the cellular proliferation of hilar
cholangiocarcinoma cells and inhibited apoptosis. Clearly,
based on such results, HCV can lead to hepatocellular car-
cinoma (HCC). Moreover, some researchers have sug-
gested that hepatocytes and cholangiocytes have the same
progenitor cells, which are hepatic progenitor cells, espe-
cially in ICC and HCC [37]. Therefore, it is possible that
HCV induces carcinogenesis in cholangiocytes and hepa-
tocytes by the same mechanism. Recently, HCV RNA has
been detected in ICC specimens, which further indicates
the potential role of HCV infection in the pathogenesis of
ICC [36,38,39]. Since HCV RNA or its components can
be detected in bile duct epithelium [40,41], our results
demonstrate a slight positive association between HCV in-
fection and ECC. HCV infection can increase the risk of
ECC by 1.75%. This conclusion is consistent with studies
by both Welzel et al. [12] and Shaib et al. [14]. However,
Qu et al. [24] found that the seroprevalence of anti-HCV
was 4.3% in ECC patients and 5.6% in patients with benign
biliary disease but without significant differences. HCV in-
fection has been shown to be associated with ICC and its
increasing incidence, but not with ECC or its incidence
[14]. Similarly, Matsumoto et al. [42] also found that
HCV-Ab was 20% in ICC patients and 7.4% in ECC pa-
tients [42]. Results of both of these studies explain that
HCV is the major risk factor for ICC but not for ECC.
This meta-analysis has several limitations that should
be considered when interpreting the results. First, con-
ducting randomized clinical trials was not feasible for an
observational study of HCV and the risk of CCA. All
studies included in this meta-analysis were case-control
studies that might introduce selection and recall biases,
which may possibly distort the true associations between
HCV and CCA. Second, seropositivity for anti-HCV was
used as the sole marker of HCV infection, and thedefinition of HCV infection was not stated in most
studies, therefore a common definition may be lacking.
Occult HCV infection might also play a role in the de-
velopment of CCA. Thus, for these reasons, the HCV ef-
fect may be underestimated. Third, the diagnostic
misclassification of cholangiocarcinoma (that is, hilar
cholangiocarcinoma classification as intrahepatic or ex-
trahepatic tumors) might result in a mismatch of true
ICC or ECC.
Conclusions
The results of the present study reveal that HCV is
associated with the significantly increasing risk of CCA,
including ICC and ECC, especially ICC. Further studies
are warranted to gain a better understanding of the pre-
cise mechanism between HCV and CCA.
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